Home » Stocks » Biodesix

Biodesix, Inc. (BDSX)

Biodesix will go public soon. The estimated IPO date is October 28, 2020.
Stock Price: $17.00 - $19.00
Current IPO price range

Stock Price Chart

Key Info

Market Cap 475.57M
Revenue (ttm) 21.55M
Net Income (ttm) -34.10M
Shares Out 26.42M
EPS (ttm) -1.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 475.57M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 26.42M
Float n/a
EPS (basic) n/a
EPS (diluted) -1.29
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield -7.17%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 22.07
PB Ratio n/a
Revenue 21.55M
Operating Income n/a
Net Income -34.10M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin -158.24%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue24.5520.43
Revenue Growth20.16%-
Net Income / Loss-30.73-26.17
Numbers in millions USD.

Company Profile

Company Details

Full Name Biodesix, Inc.
Country United States
Employees 154
CEO Scott Hutton

Stock Information

Ticker Symbol BDSX
Stock Exchange NASDAQ
Industry Services - Medical Laboratories
Unique Identifier NASDAQ: BDSX
IPO Date October 28, 2020

Description

Biodesix is a leading data-driven diagnostic solutions company leveraging state of the art technologies with our proprietary artificial intelligence (AI) platform to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus in lung disease. By combining a technology agnostic approach with a holistic view of the patient’s disease state, we believe our solutions provide physicians with greater insights to help personalize their patient’s care and meaningfully improve disease detection, evaluation, and treatment. Our unique approach to precision medicine provides timely and actionable clinical information, which we believe improves overall patient outcomes and lowers the overall healthcare cost by reducing the use of ineffective and unnecessary treatments and procedures. In addition to our diagnostic tests, we provide biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics.